{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096173","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.090084+00:00","generated_at":"2026-05-31T09:51:07.963874+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AN2 Therapeutics reports Q2 net loss $14.4M; terminates epetraborole Phase 2/3 trial in TR-MAC lung disease","bullets":["Cash, equivalents, and investments $104.5M at June 30, 2024; runway through 2027.","Net loss $14.4M in Q2 2024 vs $15.8M in Q2 2023; R&D $12.1M, G&A $3.7M.","Terminated Phase 2/3 EBO-301 trial after sputum culture conversion at Month 6 similar between arms; PRO tool validated.","Plans to advance AN2-502998 into Phase 1 for Chagas disease in 2025 and epetraborole into Phase 2 for melioidosis.","Published study on epetraborole efficacy against M. abscessus mouse lung infection model in Antimicrobial Agents and Chemotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096173","json":"https://secwatch.observer/filing/0000950170-24-096173.json","markdown":"https://secwatch.observer/filing/0000950170-24-096173.md","text":"https://secwatch.observer/filing/0000950170-24-096173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024096173/0000950170-24-096173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024096173/antx-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:51:07.963874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}